Foundation Fighting Blindness
Foundation Fighting Blindness
Add to My Podcasts
Episodes
About
Reviews
Promote
Sumitomo Pharma Receives FDA Orphan Drug Designation for Retinitis Pigmentosa Treatment
2 minutes
Posted Mar 24, 2026 at 6:39 pm.
0:00
2:12
Add to My Queue
Download
MP3
Share
episode
Share at current time
Show notes
Potential cell therapy, DSP-3077, gains special regulatory status to support development for inherited retinal disease.
Previous
Octant Bio Begins Clinical Testing Oral Treatment for Rhodopsin-Related Retinitis Pigmentosa
Next
VeonGen Reports Promising Clinical Progress for Stargardt Disease Gene Therapy
← See all 261 episodes of Foundation Fighting Blindness